Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W

Open source

DOI: 10.1016/s0140-6736(17)33108-2
Published: 2018 Feb 17
Container: Lancet (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-17-33108-2,
  title = {Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.},
  author = {Wang M and Rule S and Zinzani PL and Goy A and Casasnovas O and Smith SD and Damaj G and Doorduijn J and Lamy T and Morschhauser F and Panizo C and Shah B and Davies A and Eek R and Dupuis J and Jacobsen E and Kater AP and Le Gouill S and Oberic L and Robak T and Covey T and Dua R and Hamdy A and Huang X and Izumi R and Patel P and Rothbaum W and Slatter JG and Jurczak W},
  year = {2018},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(17)33108-2},
  url = {https://doi.org/10.1016/s0140-6736(17)33108-2}
}

RIS

TY  - JOUR
TI  - Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
AU  - Wang M
AU  - Rule S
AU  - Zinzani PL
AU  - Goy A
AU  - Casasnovas O
AU  - Smith SD
AU  - Damaj G
AU  - Doorduijn J
AU  - Lamy T
AU  - Morschhauser F
AU  - Panizo C
AU  - Shah B
AU  - Davies A
AU  - Eek R
AU  - Dupuis J
AU  - Jacobsen E
AU  - Kater AP
AU  - Le Gouill S
AU  - Oberic L
AU  - Robak T
AU  - Covey T
AU  - Dua R
AU  - Hamdy A
AU  - Huang X
AU  - Izumi R
AU  - Patel P
AU  - Rothbaum W
AU  - Slatter JG
AU  - Jurczak W
PY  - 2018
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(17)33108-2
UR  - https://doi.org/10.1016/s0140-6736(17)33108-2
ER  -

APA

M, W., S, R., PL, Z., A, G., O, C., SD, S., G, D., J, D., T, L., F, M., C, P., B, S., A, D., R, E., J, D., E, J., AP, K., S, L. G., L, O., T, R., T, C., R, D., A, H., X, H., R, I., P, P., W, R., JG, S., & W, J. (2018). Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(17)33108-2

Source records

pubmed · retrieved 2026-09-25T17:50:20.587Z